A purple and cyan fibril graphicA purple and cyan fibril graphic

Improving the Treatment & Diagnosis of Systemic Amyloidosis

Urgent Unmet Medical Needs

And Our Strategies To Address Them

Systemic amyloidosis patient landscape

Overview & Prevalence

Amyloid diseases are a diverse group of disorders, characterized by the deposition of protein fibrils called amyloid in vital organs and tissues. They are severely debilitating, progressive, and often fatal within 5 years of diagnosis.

Patients worldwide
Over 80%
of patients are undiagnosed
>1.5 years
from 1st symptoms to diagnosis
Avg. number of doctors seen prior to diagnosis

Diagnostic and treatment landscape

Opportunity to build upon early successes & expand subtype target scope

There are no FDA-approved diagnostics for systemic amyloidosis.  Patients currently must undergo a multitude of diagnostic tests to arrive at a diagnosis, and none of these tests can visualize the extent and localization of amyloid deposition across the entire body.

Out of approximately 30 amyloid disorders, only 1 has an FDA-approved treatment.  Current therapeutics for AL and ATTR work by reducing the pre-cursor protein, resulting in the reduction of new amyloid, which may slow disease progression. However, none of these therapeutics directly address already deposited toxic amyloid in organs and tissues.

Total subtypes of amyloidosis exist
Only 1 of 30
types of amyloidosis has FDA-approved therapies
0 out of 30
have FDA-approved diagnostics
Type: ATTR
3 FDA-approved treatments available
Type: AL
Only unapproved treatments available
to advance disease understanding, develop transformative diagnostics & innovative therapeutics

Illuminating to innovate, with our proprietary science

Earlier detection & the potential for better treatment for 30 types of amyloid diseases

Attralus is developing novel pan-amyloid targeting agents that have the potential to illuminate the disease with our first-in-class diagnostic imaging agent as well as directly bind and remove toxic amyloid fibrils from organs and tissues when armed with our therapeutics. Our diagnostic and therapeutic programs provide the potential for a holistic approach for detecting, monitoring, targeting, and clearing systemic amyloid.

Camera iris icon representing imaging diagnostics
Peptide Imaging Agent
Diagnostic & Monitoring
An icon of a heart floating above an open-palmed hang, representing therapeutics
Peptide-antibody fusion
Innovative Therapeutic
An icon of a heart floating above an open-palmed hang, representing therapeutics
Undisclosed Fc-fusion protein
Innovative Therapeutic
Background image of South San Francisco

About Attralus

Approach & History

Our goal at Attralus

is to improve the diagnosis and treatment of systemic amyloid diseases to increase patient survival and quality of life. Our approach targets the underlying pathology in all systemic amyloidosis diseases allowing us the potential to develop treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.

Founded in 2019

and headquartered in South San Francisco, Attralus is a clinical-stage biopharmaceutical company focused on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company’s novel, pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis.

What's New?

News, Press Releases, & Media
Attralus to Present Clinical Data at Upcoming Virtual ASH 2020Attralus to Present Clinical Data at Upcoming Virtual ASH 2020
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Press Releases
Nov 5, 2020

our apologies


Please view on a desktop or laptop computer.

Get in Touch

Partnership, Careers, Press, OR PATIENT Inquiries

Thank you

Your message has been received!

We will reply as soon as possible.
Oops! Something went wrong while submitting the form.
A purple and cyan fibril graphic
close button😔

Attralus Job

AD/Director, Program Management
Attralus, Inc., (formerly Aurora Bio) is a VC funded privately held development stage biotechnology company focused on improving the lives of systemic amyloidosis patients, through the development of novel diagnostics and therapeutics...
Read More

AD/Director, Program Management

<< Back


Attralus, Inc., (formerly Aurora Bio) is a VC funded privately held development stage biotechnology company focused on improving the lives of systemic amyloidosis patients, through the development of novel diagnostics and therapeutics. We are developing pan-amyloid targeting agents that facilitate diagnosis, and the development of novel immunotherapies designed to clear amyloid fibrils in patients with systemic amyloid diseases. We aim to improve the diagnosis and treatment of systemic amyloid diseases, such as light chain (AL), transthyretin (ATTR), and LECT2 amyloidosis, to increase patient survival and quality of life.

Attralus’ technology has broad applications and the potential to address up to 30 systemic amyloid based diseases.  Attralus has a diagnostic imaging agent currently in a ph 1/2 trial, positioned to potentially be the first approved diagnostic specifically for amyloidosis. The company also has 2 novel therapeutic fusion proteins, directed at amyloid removal, that are in pre-clinical development

Headquartered in South San Francisco and founded in 2019, Attralus has recently completed a Series A funding with VenBio to carry forward its mission to improve the lives of systemic amyloidosis patients


The AD/Director, Program Management will be responsible for providing both strategic and hands-on program and project management expertise. Initially reporting directly to the CEO, the AD/Director will be responsible for creating the program plan and budget and providing daily coordination and tracking of critical activities, assuring all milestones and deliverables are met. The Director will be responsible for developing the program management processes and procedures for the company, determining appropriate software and other tools, structuring regular meetings and communication within the company and with external collaborators.


Collaborate with the management team to provide project management leadership and execution activities within the company and between external partners and Attralus teams.

Develop and execute integrated cross-functional project plans with established goals, milestones, timelines and budget, with a key focus on bringing pre-clinical therapeutic programs into early clinical development

Conduct and direct day-to-day program activities to meet milestones; monitoring critical path activities to ensure delivery of program objectives.

Drive planning for key drug development milestones.

Maintain effective communication with the management team through oral and written correspondence and ensure adequate documentation of each communication. 

Always use/model/maintain/promote best practices in Program Management, including the use of agendas, minutes, dashboards, maintain document repository, establish and implement templates, tools, and processes to drive efficiency, alignment, communication, and effective planning.

Create and maintain easily accessible, high level program documents in electronic format. 

Recommend, manage and train on necessary software and tools.

Identify, develop and/or maintain an appropriate electronic platform (SharePoint, Shared Folders, etc.) for reporting/archiving/documentation of relevant program information, records, etc. 

Conduct risk management, contingency and scenario planning using appropriate program management tools.

Identify program issues or resource gaps and facilitate resolution.

Communicate program information and support development of program presentations to senior leadership, board members, investors and other key stakeholders as appropriate.

Contribute to budgetary planning at the program level.

Facilitate adherence to Aurora’s governance processes; work with key stakeholders to prepare for those interactions; lead/support as appropriate. Ensure implementation of governance decisions.


Minimum of a BA/BS in a scientific disciplined is required, Advance degree preferred

7+ years of program management or equivalent experience in a pharmaceutical or biotechnology organization.

Experience with research/pre-clinical and early clinical development project planning required. PM Certification is a plus.

Rare disease experience a strong plus (not required).

Desire and ability to work in a start-up, fast paced organization where you will wear many hats.

Must have excellent verbal and written communication skills as well as exceptional organizational capability.

Ability to drive program plans and timelines (across multiple functional areas) is essential.  Proven success in goal setting, prioritization and time management is required.

Understanding of FDA and/or EMA quality and regulatory processes. Prior experience with regulatory filings is desirable. 

Experience working with external partners is desirable.

Ability to work independently in decision-making and resolution of program obstacles and conflicts.

Familiarity with developing budgets and forecasting is desirable.

Ability to function autonomously, with an appreciation of detail while being cognizant of “the big picture.”

Have a patient-first mindset. All decisions made with patients in mind.

Proficiency with Microsoft Word, Excel, PowerPoint, and Project is required.

Benefits/Equal Opportunity Employer

Attralus, Inc. offers both comprehensive benefits and Paid Time Off (PTO) plans for employees, which begin on the first day of employment.

Attralus, Inc. is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.